Static and dynamic assessment of biomarkers in surgical patients with severe sepsis

Surgical Infections

Volumn 5, Issue 3, 2004, Pages 261-268

  Lowry, Stephen F ^a   Awad, Samir ^b   Ford, Henri ^c   Cheadle, William ^d   Williams, Mark D ^e   Qualy, Rebecca L ^e   McCollam, Jill Shwed ^e   Bates, Becky M ^e   Fry, Donald E ^f   Barie, Philip S ^g   Beilman, Gregory ^h   Fink, Mitchell ⁱ   Johnson, Steven ^j   Rodman, George ^k  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; D DIMER; DROTRECOGIN; INTERLEUKIN 6; PLACEBO; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INFUSION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; SURGICAL TECHNIQUE; THROMBOCYTE COUNT;

ANALYSIS OF VARIANCE; APACHE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INTERLEUKINS; MALE; PARTIAL THROMBOPLASTIN TIME; PROBABILITY; PROGNOSIS; PROTEIN C; RECOMBINANT PROTEINS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, OPERATIVE; SURGICAL WOUND INFECTION; SURVIVAL ANALYSIS;

EID: 7744246745     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2004.5.261     Document Type: Article

References (19)

1. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM Consensus Conference on sepsis and organ failure. Chest 1992;101:1481-1483.
2. Barie PS, Hydo LJ. Epidemiology of multiple organ dysfunction syndrome in critical surgical illness. Surg Infect 2000;1:173-186.
3. Nichols RL, Raad II. Management of bacterial complications in critically ill patients: Surgical wound and catheter-related infections. Diagn Microbiol Infect Dis 1999;33:121-130.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Barie PS, Williams MD, McCollam JS, et al. Benefit/ risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220.
7. ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999;82:713-717.
8. Loisa P, Rinne T, Lame S, et al. Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 2003;47:319-325.
9. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004;32:S223-S228.
10. Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004;8: R82-R90.
11. Dhainaut JF, Yan SB, Dhainaut JF, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642-653.
12. Pape HC, van Griensven M, Rice J, et al. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: Determination of the clinical relevance of biochemical markers. J Trauma 2001;50:989-1000.
13. Giannoudis PV, Smith RM, Bellamy MC, et al. Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit. J Bone Joint Surg Br 1999;81:356-361.
14. Rezende-Neto JB, Moore EE, Melo de Andrade MV, et al. Systemic inflammatory response secondary to abdominal compartment syndrome: Stage for multiple organ failure. J Trauma 2002;53:1121-1128.
15. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 1996;24:163-172.
16. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-195.
17. Nijsten MW, de Groot ER, ten Duis HJ, et al. Serum levels of interleukin-6 and acute phase responses. Lancet 1987;2:921.
18. Vervolet MG, Thijs LG, Hack CE. Derangement of coagulation and fibrinolysis and in critically ill patients with sepsis and septic shock. Semin Thomb Hemost 1998;24:33-44.
19. Macias WL, Dhainaut JF, Yan SB, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharm Ther 2002;72:391-402.